Jefferies on MapLight Therapeutics (MPLT): 'Cleaner Catalyst Flow as Competitor Pushes Back Alz Psychosis Data to YE:26'
Tweet Send to a Friend
Jefferies analyst Andrew Tsai reiterated a Buy rating and $32.00 price target on MapLight Therapeutics (NASDAQ: MPLT).The analyst comments "In ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
